Skip to main content

Table 2 Circulating tumor cells detection according to denosumab treatment and bone metastasis

From: Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

  Number of samples No CTCs CTCs P value Estimate (95% CI) P value Estimate (95% CI)
Reference 28 12 (43%) 16 (57%) Reference  
Bone metastasis 24 11 (46%) 13 (54%) 1.000 0.89 (0.26–3.05) Reference  
Bone metastasis and denosumab 20 16 (80%) 4 (20%) 0.017 0.19 (0.04–0.81) 0.030 0.22 (0.04–0.96)
  1. The table shows the number of patients with and without circulating tumor cells (CTCs) among individuals with bone metastasis who were treated or not with denosumab